Last reviewed · How we verify
NCT06055088
Hand-Foot Exercises on Peripheral Neuropathy
NA trial testing Hand and foot exercise in Breast Cancer in 79 participants. Completed in 16 February 2024.
16 February 2024
Quick facts
| Lead sponsor | Amasya University |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | supportive care |
| Enrollment | 79 |
| Start date | 1 June 2023 |
| Primary completion | 16 February 2024 |
| Estimated completion | 16 February 2024 |
| Sites | 1 location across Turkey (Türkiye) |
Drugs / interventions tested
- Hand and foot exercise
Conditions studied
- Breast Cancer — all drugs for Breast Cancer →
- Neuropathy — all drugs for Neuropathy →
Sponsor
Amasya University
Who can join
Adults 18 to 80, female only, with Breast Cancer or Neuropathy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study will be conducted to compare the effects of hand and foot exercises on peripheral neuropathy and quality of life in breast cancer patients taking taxanes
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
The effect of hand and foot exercises on peripheral neuropathy and quality of life in women with breast cancer: a randomized controlled trial.
Uysal N, Ünal Toprak F. · · 2025 · cited 1× · PMID 39779496 · DOI 10.1007/s00520-025-09145-x
Verify or expand the search:
- PubMed search for NCT06055088
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Breast Cancer
Currently open trials in the same condition.
- NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
- NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
- NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
- NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
- NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting
Other Amasya University trials
Trials by the same sponsor.
- NCT07512999 — The Effect of Using Nature Sounds and Virtual Reality During the Non-Stress Test · NA · not yet recruiting
- NCT07510555 — The Effect of a Mindfulness-Based Stress Reduction Program Applied to Nulliparous Pregnant Women · NA · not yet recruiting
- NCT07485790 — The Effects of Yoga on Pregnant Women · NA · recruiting
- NCT07360392 — BiFeS vs. iPACK in Postoperative Knee Arthroplasty Analgesia · NA · not yet recruiting
- NCT07343414 — Effect of Anesthesia Technique on Surgical View in Shoulder Arthroscopy · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06055088 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Amasya University
- Last refreshed: 20 February 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06055088.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing